Mylan Ireland Limited Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Mylan Ireland Limited Pharmaceutical Import Records from India — 10 Products, $54.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Ireland Limited — Pharmaceutical Importer Profile (2026) | 10 Products, $54.2M Trade | TransData Nexus

Mylan Ireland Limited

Pharmaceutical Importer · Netherlands · Respiratory Focus · $54.2M Total Trade · DGFT Verified

Mylan Ireland Limited is a pharmaceutical importer based in Netherlands with a total trade value of $54.2M across 10 products in 7 therapeutic categories. Based on 1,118 verified import shipments from Indian Customs (DGFT) records, Mylan Ireland Limited is the #1 buyer in 2 products including Fluticasone, Trastuzumab. Mylan Ireland Limited sources from 19 verified Indian suppliers, with Cipla Limited accounting for 32.5% of imports.

Mylan Ireland Limited — Import Portfolio & Supplier Network

Mylan Ireland Limited import network — 10 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Ireland Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$9.8M	324	32.5%
Mylan Laboratories Limited	$9.0M	247	29.8%
Intas Pharmaceuticals Limited	$3.3M

What Formulations Does Mylan Ireland Limited Import?

Formulation	Value	Ships
Dymista azelastine hydrochloride 137mcg	$2.8M	55
Dymista (azelastine hydrochloride 137mcg+fluticasone propionate 50mcg (per spray) nasal suspension);dymista trade Pack	$2.2M	48
Dymista (azelastine hydrochloride 137mcg+fluticasone propionate 50mcg (per spray) nasal suspension);dymista trade Pack	$700.0K	14
Pharma drug&med: apixaban 5MG	$551.5K	21
Dymista azelastine hydrochloride 137mcg+fluticasone propionate 50mcg per spray nasal suspension;dymista trade Pack	$550.0K	11
Pharma drug&med: apixaban 5MG	$350.7K	13
Cefixime tablets 200MG (cefixime	$350.0K	7
Dymista trade Pack azelastine	$350.0K	7
Cefixime tablets 200MG (cefixime viatris200 MG)	$349.2K	14
Fusidic acid and betamethasone	$345.4K	10
Metformine viatris 500 MG 6x10s-viatris/belgium-pc464 metformine mylan 500 MG	$333.5K	18
Olmesartan medoxomil and	$310.5K	9
Dymista trade Pack (azelastine hydrochloride 137 MCG and fluticasonepropionate 50 MCG nasal spray);dymista trade Pack	$300.0K	6
Dymista (azelastine hydrochloride 137mcg+fluticasone propionate 50mcg(per spray)nasal suspension);dymista trade Pack	$300.0K	6
Metformin viatris metformin	$286.6K	8

Mylan Ireland Limited imports 503 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 10 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluticasone	Respiratory	$24.3M	485	8.6%	1
2	Ras	Ayurvedic & Herbal Products	$10.6M	211	1.8%	2
3	Trastuzumab	Advanced Oncology	$8.8M	176	7.0%	1
4	Apixaban	Cardiovascular	$6.3M	127	3.5%	3
5	Cefixime	Advanced Antibiotics	$1.8M	54	1.0%	10
6	Flucloxacillin	Advanced Antibiotics	$1.6M	48	4.2%	4
7	Dapagliflozin	Advanced Diabetes Medications	$500.0K	10	1.0%	3
8	Sulfasalazine	Gastrointestinal	$115.1K	3	3.6%	8
9	Epirubicin	Advanced Oncology	$100.0K	2	1.6%	4
10	Minocycline	Advanced Antibiotics	$100.0K	2	0.4%	8

Mylan Ireland Limited imports 10 pharmaceutical products across 7 categories into Netherlands totaling $54.2M. The company is the #1 buyer for 2 products: Fluticasone, Trastuzumab.

Mylan Ireland Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Ireland Limited is a pharmaceutical importer and buyer based in the Netherlands, specializing in the acquisition of finished pharmaceutical formulations from India. As a subsidiary of Viatris, a global healthcare company formed in 2020 through the merger of Mylan and Upjohn, Mylan Ireland Limited plays a pivotal role in the distribution of generic and specialty pharmaceuticals within the European market.

The company's operations are integral to the Netherlands' pharmaceutical supply chain, serving as a key conduit for the importation of a diverse range of medicinal products. By sourcing high-quality generics from India, Mylan Ireland Limited contributes to the availability and affordability of essential medications across Europe.

2Distribution Network

Mylan Ireland Limited's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout the Netherlands and beyond. While specific warehouse locations are not publicly disclosed, the company collaborates with established logistics partners to facilitate the timely importation and distribution of medicines. This network is supported by robust logistics capabilities, including compliance with the European guidelines on Good Distribution Practice (GDP) of medicinal products for human use. (business.gov.nl)

The company's geographic coverage extends throughout the Netherlands, ensuring that imported pharmaceutical products are accessible to a wide range of healthcare providers and patients. Additionally, Mylan Ireland Limited's affiliation with Viatris enhances its ability to leverage a broader European distribution network, facilitating the efficient movement of products across the continent.

3Industry Role

In the Netherlands' pharmaceutical supply chain, Mylan Ireland Limited functions primarily as a pharmaceutical importer and buyer. The company is not involved in manufacturing or direct sales to end-users but focuses on sourcing and importing finished pharmaceutical formulations from India. This role positions Mylan Ireland Limited as a critical intermediary, ensuring the availability of a wide array of generic and specialty medicines within the Dutch market.

By importing these products, Mylan Ireland Limited supports the Dutch healthcare system by enhancing the accessibility and affordability of essential medications. The company's operations are aligned with the European Union's objectives of promoting competition and reducing healthcare costs through the availability of generic medicines.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Ireland Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Ireland Limited's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 95.5% of the total import value from India. This concentration is particularly notable in the respiratory and advanced oncology therapeutic categories, where the company imports significant volumes of fluticasone and trastuzumab. Such a focused sourcing approach may indicate a strategic decision to concentrate on high-demand, high-value products, potentially leveraging economies of scale and supplier relationships.

However, this concentration also introduces risks associated with dependency on a limited number of products and suppliers. Any disruptions in the supply chain for these key products could have a disproportionate impact on Mylan Ireland Limited's operations. The company's reliance on a diverse set of Indian suppliers, including CIPLA Limited and Mylan Laboratories Limited, suggests an effort to mitigate such risks by not depending on a single source. Nonetheless, the overall high concentration underscores the importance of robust supply chain management and contingency planning.

2Supply Chain Resilience

Mylan Ireland Limited's supply chain resilience is supported by its diversified sourcing strategy, engaging multiple Indian suppliers to mitigate risks associated with single-source dependency. The company's importation of 503 unique pharmaceutical formulations indicates a broad product portfolio, which can help buffer against market fluctuations and supply disruptions.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Medicines Evaluation Board (MEB) serves as the primary regulatory authority overseeing the authorization and supervision of medicinal products. The MEB ensures that all pharmaceutical products meet the necessary safety, efficacy, and quality standards before they are marketed. (english.cbg-meb.nl)

Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for the importation, distribution, and sale of medicinal products. Additionally, the Commodities Act (Warenwet) provides general rules on public health, product safety, fairness of trade, and proper information, applicable to all consumer products, including medicines. (business.gov.nl)

The marketing authorization pathway for Indian generics involves obtaining a parallel import marketing authorization from the MEB. This process requires demonstrating that the imported product is therapeutically equivalent to an already authorized product in the Netherlands and complies with all regulatory standards. (english.cbg-meb.nl)

2Import Licensing & GMP

Importers of medicinal products into the Netherlands must obtain a manufacturer's permit if they prepare or import medicines from outside the European Economic Area (EEA). This permit is issued by Farmatec, an executive body of the Ministry of Health, Welfare and Sport (VWS). (business.gov.nl)

Mylan Ireland Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Ireland Limited's focus on importing products in the respiratory, Ayurvedic & herbal, and advanced oncology therapeutic categories aligns with market demand for these treatments. The significant importation of fluticasone, a corticosteroid used in respiratory conditions, and trastuzumab, a monoclonal antibody for advanced oncology, indicates a strategic emphasis on high-demand, high-value products. This strategy caters to prevalent health concerns and leverages the company's expertise in these therapeutic areas.

The company's importation of Ayurvedic and herbal products reflects a growing consumer interest in alternative and complementary medicine. By incorporating these products, Mylan Ireland Limited diversifies its portfolio and meets the evolving preferences of the Dutch market.

2Sourcing Profile

Mylan Ireland Limited's sourcing strategy is centered on importing generic drugs from India, focusing on finished pharmaceutical formulations. This approach allows the company to offer a broad range of products without the complexities associated with raw material procurement. India's robust pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a reliable source for these formulations.

The company's preference for finished formulations aligns with its role as an importer and distributor, facilitating efficient market entry and distribution within the Netherlands. By sourcing from India, Mylan Ireland Limited leverages cost advantages and a diverse product range, enhancing its competitiveness in the European market.

Frequently Asked Questions — Mylan Ireland Limited

What products does Mylan Ireland Limited import from India?

Mylan Ireland Limited imports 10 pharmaceutical products across 7 categories. Top imports: Fluticasone ($24.3M), Ras ($10.6M), Trastuzumab ($8.8M), Apixaban ($6.3M), Cefixime ($1.8M).

Who supplies pharmaceuticals to Mylan Ireland Limited from India?

Mylan Ireland Limited sources from 19 verified Indian suppliers. The primary supplier is Cipla Limited (32.5% of imports, $9.8M).

What is Mylan Ireland Limited's total pharmaceutical import value?

Mylan Ireland Limited's total pharmaceutical import value from India is $54.2M, based on 1,118 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Ireland Limited focus on?

Mylan Ireland Limited imports across 7 categories. The largest: Respiratory (44.7%), Ayurvedic & Herbal Products (19.5%), Advanced Oncology (16.4%).

Get Full Mylan Ireland Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Mylan Ireland Limited

Mylan Ireland Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Mylan Ireland Limited?

What Formulations Does Mylan Ireland Limited Import?

What Products Does Mylan Ireland Limited Import?

Top Products by Import Value

Mylan Ireland Limited Therapeutic Categories — 7 Specializations